Seizure and Prison for Owner of Immuno Biotec
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
After a four-year investigation by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) (and with the support of the London Regional Asset Recovery Team, RART), the owner of Guernsey-based Immuno Biotech is now facing a £1.4 million seizure, including private property.
He has already served a 15-month prison sentence based on four counts of manufacturing, selling and supplying an unlicensed drug (plus one for money laundering).
Immuno Biotech was a distributor of a human blood product called Globulin component Macrophage Activating Factor (GcMAF). GcMAF was advertised and sold over the Internet as a so-called "miracle cure" for various diseases and conditions. Following an investigation, the MHRA confiscated more than 10,000 vials of the product and issued a warning to the public.
Source: GOV.UK provided by the Government Digital Service.
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?